[{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Hansoh Pharma"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Hercules Capital","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Hercules Capital"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"FDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ FDA","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ FDA"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"Glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"1,3-Beta-D-glucan synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"SCY-247","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Scynexis \/ National Institutes of Health"},{"orgOrder":0,"company":"Scynexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Not Applicable"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0.58999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0.58999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"Hansoh Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Scynexis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Scynexis \/ Hansoh Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ Hansoh Pharma"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Scynexis","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.58999999999999997,"dosageForm":"Tablet, Film Coated","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Scynexis \/ GSK"},{"orgOrder":0,"company":"Scynexis","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ibrexafungerp Citrate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Scynexis","amount2":0.58999999999999997,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Scynexis \/ GSK","highestDevelopmentStatusID":"12","companyTruncated":"Scynexis \/ GSK"}]
Find Clinical Drug Pipeline Developments & Deals by Scynexis
Details :
Under the agreement, GSK has the rights to develop GSK5458448/SCY-078 (ibrexafungerp), a novel oral glucan synthase inhibitor and commercialize Brexafemme in all countries except the greater China.
Details :
GSK acquired the rights to develop and commercialize GSK5458448 (ibrexafungerp), a glucan synthase inhibitor, and market Brexafemme for antifungal indications outside China.
Details :
Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, approved for vulvovaginal candidiasis and RVVC, is being develop in phase 3 trials for the potential treatment of invasive candidiasis.
Details :
Under the agreement GSK gains right to commercialize Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, for vulvovaginal candidiasis and RVVC while continuing to develop ibrexafungerp, in phase 3 trials for the potential treatment of invasive...
Details :
Under the agreement, GSK has the rights to develop ibrexafungerp, a novel oral glucan synthase inhibitor with a broad spectrum of activity and commercialize Brexafemme (ibrexafungerp tablets) in all countries except the greater China region.
Details :
Under the agreement, GSK gains rights to commercialise Brexafemme, a first-in-class antifungal for the treatment of VVC and for reduction in the incidence of RVVC while continuing to develop ibrexafungerp, which is in phase III trials for the potential t...
Details :
Brexafemme (ibrexafungerp) is a novel oral triterpenoid antifungal approved for the treatment of vulvovaginal candidiasis (VVC). Its mechanism of action, glucan synthase inhibition, is fungicidal against Candida species, meaning it kills fungal cells.
Details :
NIH to investigate a second generation fungerp (SCY-247) developed by SCYNEXIS as a potential treatment for Candida auris (C.auris), a multidrug-resistant yeast that causes serious and often deadly infections.
Details :
Brexafemme (Ibrexafungerp) is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
Details :
Cumulative interim analysis of outcomes by fungal disease type highlighted in a platform presentation demonstrates 82.3% positive clinical outcomes in patients treated with brexafemme (ibrexafungerp).
Reset All
